Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alkermes plc ALKS

Healthcare Biotechnology
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products,... see more

Recent & Breaking News (NDAQ:ALKS)

Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board

PR Newswire June 20, 2023

Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board

Business Wire June 15, 2023

Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes

Business Wire June 13, 2023

Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors

PR Newswire June 13, 2023

Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board

Business Wire June 9, 2023

Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation

PR Newswire June 8, 2023

Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations

PR Newswire June 6, 2023

Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders

Business Wire June 5, 2023

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

PR Newswire June 1, 2023

Alkermes to Participate in Two Upcoming Investor Conferences

PR Newswire May 31, 2023

Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value

PR Newswire May 25, 2023

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences

PR Newswire May 16, 2023

Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire May 9, 2023

Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process

PR Newswire May 8, 2023

Alkermes plc Reports First Quarter 2023 Financial Results

PR Newswire April 26, 2023

Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration

PR Newswire April 25, 2023

Alkermes to Report First Quarter Financial Results on April 26, 2023

PR Newswire April 19, 2023

Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer

PR Newswire April 19, 2023

Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business

PR Newswire April 18, 2023

Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness

PR Newswire March 23, 2023